Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Golexanolone - Umecrine Cognition

Drug Profile

Golexanolone - Umecrine Cognition

Alternative Names: GR-3027

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Umecrine Cognition
  • Class Alkynes; Androstanes; Hepatoprotectants; Imines; Neuroprotectants; Small molecules
  • Mechanism of Action GABA-A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypersomnia
  • Phase I/II Hepatic encephalopathy

Most Recent Events

  • 02 Aug 2019 Chemical structure information added
  • 12 Dec 2018 Umecrine Cognition has patent protection for golexanolone (GR 3027) for its use in hepatic encephalopathy in European Union
  • 19 Oct 2018 Umecrine Cognition completes a phase IIa trial in Hypersomnia in Finland, Denmark and Sweden (EudraCT2017-002127-16)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top